Pacira BioSciences, Inc. (PCRX) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

16/25

Growth 4 Margin 3 Expansion 4 Platform 1 Financial 4

latest quarter score

Earnings Reports

16
Pacira BioSciences (PCRX) Q2 2026: UnitedHealthcare Win Expands Covered Lives to 150M, Shifting Outpatient Growth Trajectory
August 05, 2026
23
PACIRA (PCRX) Q1 2026: Expirel Volume Grows 7% as 5x30 Strategy Drives Durable Franchise Momentum
May 01, 2026
16
PACIRA (PCRX) Q4 2025: 102M Covered Lives Drive XBRL Access Surge, Margin Expansion On Track
February 27, 2026
20
Pacira Biosciences (PCRX) Q3 2025: Expirel Volumes Up 9% as GPO Strategy Drives Market Penetration
November 10, 2025
20
PCRX Q2 2025: Gross Margin Rises to 82% as Manufacturing Efficiencies Accelerate
August 06, 2025
17
Pacira Biosciences (PCRX) Q1 2025: Xpirel Volume Up 7% as No Pain Reimbursement Drives Early Uptake
July 05, 2025
Pacira BioSciences (PCRX) Q4 2024: 5x30 Strategy Sets Stage for Double-Digit Growth and Innovation
February 27, 2025

Browse all companies